Pure Global

Novel Index (PIMR) in PAH - Trial NCT05812976

Access comprehensive clinical trial information for NCT05812976 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, Los Angeles and is currently Recruiting. The study focuses on Pulmonary Hypertension. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05812976
Recruiting
other
Trial Details
ClinicalTrials.gov โ€ข NCT05812976
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Novel Index (PIMR) in PAH
Impact of the Pulmonary Index of Microcirculatory Resistance in Pulmonary Arterial Hypertension

Study Focus

Pulmonary Hypertension

Pulmonary Index of Microcirculatory Resistance

Observational

other

Sponsor & Location

University of California, Los Angeles

Los Angeles, United States of America

Timeline & Enrollment

N/A

Feb 01, 2023

Feb 01, 2025

50 participants

Primary Outcome

PAH hospitalization or all-cause mortality at 1 year,PIMR change from baseline,RV-IMR

Summary

The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small
 arteries. In the heart, the invasive measurement of the resistance of the small arteries has
 been shownto be safe, easy, reliable, and prognostic. This study is intended to translate
 prior work in heart arteries to the PAH space and invasively measure the resistance of the
 small arteries of the lung (pulmonary index of microcirculatory resistance [PIMR]) and the
 coronary artery supplying the right ventricle (acute marginal of the RCA; RV-IMR).
 Importantly, these measurements will be made during standard of care cardiac catheterizations
 (right heart catheterization [RHC] +/- left heart catheterization). The correlation between
 these new indices and the standard ones measured during RHC typically used to determine the
 severity of pulmonary hypertension will be analyzed. In addition, among newly diagnosed
 patients, the study will evaluate how these indices change 6 months after starting treatment.
 Finally, the association of these indices with clinical outcomes at 1 year will be assessed.
 The findings from this study may deliver an immediate impact to patient care by identifying a
 new metric to help better identify those who may benefit from a more intensive, personalized
 treatment regimen.

ICD-10 Classifications

Primary pulmonary hypertension
Other secondary pulmonary hypertension
Pulmonary heart disease and diseases of pulmonary circulation
Pulmonary heart disease, unspecified
Pulmonary valve disorders

Data Source

ClinicalTrials.gov

NCT05812976

Non-Device Trial